ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Core Insights - ArriVent BioPharma, Inc. has appointed Brent S. Rice as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology and pharmaceutical industry [1][2] - The company is focused on the commercialization of firmonertinib for EGFR mutant non-small cell lung cancer (NSCLC) and advancing its antibody drug conjugate (ADC) portfolio [2][4] Company Overview - ArriVent is a clinical-stage biopharmaceutical company dedicated to developing and commercializing differentiated medicines for cancer patients [4] - The company aims to leverage its team's drug development expertise to maximize the potential of its lead candidate, firmonertinib, and advance its pipeline of novel therapeutics [4] Leadership Experience - Brent S. Rice previously served as Senior Vice President and global Chief Commercial Officer at Autolus Therapeutics, where he led the transition from clinical stage to commercial organization [2][3] - He has extensive experience in marketing, operations, and reimbursement, and has a strong track record in launching novel therapies and building high-performing organizations [3]